Age stratified seroprevalence of antibodies against SARS CoV 2 in the pre and post vaccination era, February 2020 to March 2022, Japan
Yamayoshi, S.; Iwatsuki-Horimoto, K.; Okuda, M.; Ujie, M.; Yasuhara, A.; Murakami, J.; Duong, C.; Hamabata, T.; Ito, M.; Chiba, S.; Kobayashi, R.; Takahash, S.; Mitamura, K.; Hagihara, M.; Shibata, A.; Uwamino, Y.; Hasegawa, N.; Ebina, T.; Izumi, A.; Kato, H.; Nakajima, H.; Sugaya, N.; Seki, Y.; Iqbal, A.; Kamimaki, I.; Yamazaki, M.; Kawaoka, Y.; Furuse, Y.
Show abstract
Japan has reported a small number of COVID-19 cases relative to other countries. Because not all infected people receive diagnostic tests for COVID-19, the reported number of COVID-19 cases must be lower than the actual number of infections. Assessments of the presence of antibodies against the spike protein of SARS-CoV-2 can retrospectively determine the history of natural infection and vaccination. In this study, we assessed SARS-CoV-2 seroprevalence by analyzing over 60,000 samples collected in Japan from February 2020 to March 2022. The results showed that about 5% of the Japanese population had been infected with the virus by January 2021. The seroprevalence increased with the administration of vaccinations to adults; however, among the elderly, it was not as high as the vaccination rate, probably due to poor immune responses to the vaccines and waning immunity. The infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants among children who were not eligible for vaccination. Nevertheless, their seroprevalence was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.